+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07147231

Phase 1 and Randomized Phase 2 Study of Pidnarulex CX-5461 With Cemiplimab REGN2810 for Refractory Microsatellite Stable Colorectal Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-09-09

86

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating pidnarulex in combination with cemiplimab to study their safety, best dose, and effectiveness in treating patients with microsatellite stable colorectal cancer that no longer responds to treatment. This phase III trial aims to find the recommended dose, assess side effects, and compare how well pidnarulex alone or with cemiplimab can control disease progression and improve survival in patients with refractory metastatic colorectal cancer. The study also explores genetic and biological markers that might predict treatment response. In the first phase, patients receive cemiplimab intravenously on days 1 and 15 and pidnarulex intravenously on days 1 and 8 of each 28-day cycle for up to 26 cycles, unless disease worsens or side effects become unacceptable. The second phase randomly assigns patients to receive pidnarulex alone or both drugs with the same schedules and durations. Throughout the trial, patients undergo tumor biopsies, blood sample collections, and imaging scans including CT, MRI, or PETCT to monitor disease and treatment effects. Participants will have regular blood tests, imaging studies, and tumor biopsies to assess treatment impact and side effects. After completing treatment, patients are followed up at 30 days and then every three months for two years to monitor disease status and long-term safety. Researchers measure progression-free survival, response rates, overall survival, drug levels in blood, and biological markers from tumor and blood samples to understand how well the treatments work and their safety profile.

CONDITIONS

Brief Title

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here